MPO and Alzheimer disease: Previous studies have demonstrated significantly elevated plasma MPO levels [42, 43] and MPO-immunoreactive cells or extracellular MPO in brain regions [18, 44] among AD patients, suggesting MPO may serve as a biomarker and potential therapeutic target for AD.